AngioDynamics (ANGO) SVP Campbell Chad Thomas Receives Award

What Happened

• Campbell Chad Thomas, SVP/GM, Vascular Access at AngioDynamics (ANGO), received two awards on July 15, 2026: 16,081 restricted stock units (RSUs) and 16,081 performance rights. Both were reported as grants (transaction code A) at a reported price of $0.00 (standard for awards on Form 4).
• The RSUs are time‑based and convert to one share each as they vest (no cash exchanged). The performance rights are derivative awards that can convert into shares based on future performance; the Form 4 shows no immediate sale or purchase of publicly traded shares.

Key Details

• Transaction date: July 15, 2026; Form 4 filed July 22, 2026 (filed 7 days after the transaction).
• Reported price: $0.00 (grant/award).
• Shares granted: 16,081 RSUs + 16,081 performance rights (target).
• Shares owned after transaction: not disclosed in the excerpt of the filing.
• Footnote highlights:
  • RSU vesting: 4 equal annual installments (25% each) on July 15, 2027, 2028, 2029 and 2030. (F1)
  • Performance rights: each right can convert to one share; payout ranges from 0%–200% of target based on 3‑year total shareholder return vs. a peer group, with an additional possible ±20% adjustment on calculated achievement (for aggregate potential of up to 240% of target). Unvested/unenabled shares are forfeited. (F2)
• Timeliness: The Form 4 was filed more than the standard 2 business days after the transaction, which is later than the usual SEC Form 4 deadline.

Context

• These are compensation awards, not open‑market purchases or sales; RSUs and performance rights are common long‑term incentive tools and typically vest or pay out only if time or performance conditions are met. They do not represent immediate cash value until vested/earned and converted to shares (and possibly sold).